Total net revenue (includes product sales as well as the earnings contribution from Benicar, authorized generic sales of Lexapro, interest income and other income) is now expected to be $3.2 billion compared with previous guidance of $3.4 billion as a result of the following: As previously disclosed in June 2012, sales of Lexapro are now expected to be approximately $215 million compared to the pr